Lung cancer remains one of the most lethal malignancies, with 5-year survival rates for non-small cell lung cancer still hovering near 25% per recent SEER analyses despite incremental advances in targeted therapy and immunotherapy. Radiation therapy is a mainstay for both early and locally advanced disease, yet radioresistance frequently emerges, limiting durable local control. The April 2026 preclinical study from University of Texas MD Anderson Cancer Center, published in Cancer Research (Mao et al., DOI: 10.1158/0008-5472.can-25-3728), identifies a previously underappreciated metabolic shield: upregulation of the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH). This work goes well beyond the press release's summary by revealing how DHODH simultaneously supports nucleotide synthesis for DNA repair and generates ubiquinol to suppress lipid peroxidation and ferroptosis after radiation-induced reactive oxygen species damage.

Importantly, this is not a randomized controlled trial in humans but a preclinical investigation combining in-vitro lung cancer cell lines with orthotopic and xenograft mouse models (typical cohort sizes of 6–10 animals per arm). No conflicts of interest were reported. The authors demonstrate that DHODH inhibition using the FDA-approved rheumatoid arthritis drug leflunomide sensitizes radioresistant cells to ferroptosis. When combined with anti-PD-1 immunotherapy—which itself elevates interferon-gamma and further primes cells for lipid-peroxide accumulation—the triple regimen produced marked tumor regression where radiation plus checkpoint blockade alone failed.

This finding synthesizes directly with the same team's seminal 2021 Nature paper (Mao et al., Nature 2021;596:594–599, doi:10.1038/s41586-021-03539-7), which first established DHODH as a ferroptosis suppressor operating parallel to the canonical GPX4 pathway. It also aligns with a 2023 Nature Reviews Cancer overview on ferroptosis in therapy resistance (Lei et al., Nat Rev Cancer 2023;23:165–182) that catalogued how multiple cancers hijack mitochondrial redox systems to evade radiation and chemotherapy. What mainstream coverage, including the MedicalXpress article, largely missed is the elegant immune-metabolic crosstalk: IFN-γ secreted by activated T cells after PD-1 blockade transcriptionally represses SLC7A11 while DHODH inhibition removes the ubiquinol brake, creating synergistic lethality specific to the irradiated tumor microenvironment. Earlier reporting on radioresistance has disproportionately emphasized DNA-damage repair (e.g., EGFR, ATM pathways) while underplaying membrane lipid vulnerability.

Genuine analysis reveals this discovery fits a broader pattern of metabolic reprogramming in therapy-resistant lung cancers. Tumors under radiation stress upregulate de novo pyrimidine synthesis not merely for proliferation but for redox homeostasis—an evolutionary adaptation that leflunomide can exploit. Because leflunomide is already FDA-approved, the translational runway is unusually short; phase I/II basket trials could combine it with stereotactic body radiotherapy and modern immunotherapy regimens within 18–24 months. Yet caution is warranted: leflunomide carries known risks of hepatotoxicity, bone-marrow suppression, and interstitial lung disease—complications that could compound in patients already receiving thoracic radiation and checkpoint inhibitors. Patient selection via DHODH expression or baseline lipid-peroxidation biomarkers will likely prove essential.

By addressing a core resistance node at the intersection of metabolism, ferroptosis, and adaptive immunity, this triple strategy targets a major barrier in a disease where mainstream options for radioresistant cases remain limited to platinum doublet chemotherapy or palliative care. If clinical validation confirms the preclinical signals, survival gains could mirror the 10–15% absolute improvements historically seen when immunotherapy was added to chemoradiation in stage III NSCLC. The work underscores a larger paradigm shift: repurposing approved metabolic drugs to amplify regulated cell death pathways may offer faster, more cost-effective progress than developing entirely novel agents.